留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death

Debin Zheng,  Jingfei Liu,  Limin Xie,  Yuhan Wang,  Yinghao Ding,  Rong Peng,  Min Cui,  Ling Wang,  Yongjie Zhang,  Chunqiu Zhang,  Zhimou Yang

downloadPDF
文章导航 > 机械工程学报  > 优先出版
Debin Zheng, Jingfei Liu, Limin Xie, Yuhan Wang, Yinghao Ding, Rong Peng, Min Cui, Ling Wang, Yongjie Zhang, Chunqiu Zhang, Zhimou Yang. Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death[J]. 机械工程学报. doi: 10.1016/j.apsb.2021.07.005
引用本文: Debin Zheng, Jingfei Liu, Limin Xie, Yuhan Wang, Yinghao Ding, Rong Peng, Min Cui, Ling Wang, Yongjie Zhang, Chunqiu Zhang, Zhimou Yang. Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death[J]. 机械工程学报. doi: 10.1016/j.apsb.2021.07.005
shu
Debin Zheng, Jingfei Liu, Limin Xie, Yuhan Wang, Yinghao Ding, Rong Peng, Min Cui, Ling Wang, Yongjie Zhang, Chunqiu Zhang, Zhimou Yang. Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death[J]. JOURNAL OF MECHANICAL ENGINEERING. doi: 10.1016/j.apsb.2021.07.005
Citation: Debin Zheng, Jingfei Liu, Limin Xie, Yuhan Wang, Yinghao Ding, Rong Peng, Min Cui, Ling Wang, Yongjie Zhang, Chunqiu Zhang, Zhimou Yang. Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death[J]. JOURNAL OF MECHANICAL ENGINEERING. doi: 10.1016/j.apsb.2021.07.005
shu

Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death

doi: 10.1016/j.apsb.2021.07.005

  • a. Key Laboratory of Bioactive Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Collaborative Innovation Center of Chemical Science and Engineering, National Institute of Functional Materials, Nankai University, Tianjin 300071, China;

  • b. College of Pharmacy, Nankai University, Tianjin 300071, China;

  • c. Department of Human Anatomy, Nanjing Medical University, Nanjing 211166, China

基金项目: 

This work was supported by the National Natural Science Foundation of China (31870949, 21875116, 31961143004, 81921004, 81100942, 81472081), the National Science Fund for Distinguished Young Scholars (31825012, China) and the Tianjin Science Fund for Distinguished Young Scholars (17JCJQJC44900, China). We also thank Dr. Wenjing Li and Dr. Zhiwen Hu for their help in this work.

详细信息
    通讯作者:

    Yongjie Zhang,E-mail:zhangyongjie@njmu.edu.cn

    Chunqiu Zhang,E-mail:zhangcq@nankai.edu.cn

    Zhimou Yang,E-mail:yangzm@nankai.edu.cn

  • 中图分类号: https://www.sciencedirect.com/science/article/pii/S2211383521002549/pdf?md5=b0112dbd2daef385ca3e0f9d0f453284&pid=1-s2.0-S2211383521002549-main.pdf

Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death

  • a. Key Laboratory of Bioactive Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Collaborative Innovation Center of Chemical Science and Engineering, National Institute of Functional Materials, Nankai University, Tianjin 300071, China;

  • b. College of Pharmacy, Nankai University, Tianjin 300071, China;

  • c. Department of Human Anatomy, Nanjing Medical University, Nanjing 211166, China

Funds: 

This work was supported by the National Natural Science Foundation of China (31870949, 21875116, 31961143004, 81921004, 81100942, 81472081), the National Science Fund for Distinguished Young Scholars (31825012, China) and the Tianjin Science Fund for Distinguished Young Scholars (17JCJQJC44900, China). We also thank Dr. Wenjing Li and Dr. Zhiwen Hu for their help in this work.

    摘要
  • 摘要: Immunogenic cell death (ICD) plays a major role in cancer immunotherapy by stimulating specific T cell responses and restoring the antitumor immune system. However, effective type II ICD inducers without biotoxicity are still very limited. Herein, a tentative drug- or photosensitizer-free strategy was developed by employing enzymatic self-assembly of the peptide F-pY-T to induce mitochondrial oxidative stress in cancer cells. Upon dephosphorylation catalyzed by alkaline phosphatase overexpressed on cancer cells, the peptide F-pY-T self-assembled to form nanoparticles, which were subsequently internalized. These affected the morphology of mitochondria and induced serious reactive oxygen species production, causing the ICD characterized by the release of danger-associated molecular patterns (DAMPs). DAMPs enhanced specific immune responses by promoting the maturation of DCs and the intratumoral infiltration of tumor-specific T cells to eradicate tumor cells. The dramatic immunotherapeutic capacity could be enhanced further by combination therapy of F-pY-T and anti-PD-L1 agents without visible biotoxicity in the main organs. Thus, our results revealed an alternative strategy to induce efficient ICD by physically promoting mitochondrial oxidative stress.

     

    Abstract: Immunogenic cell death (ICD) plays a major role in cancer immunotherapy by stimulating specific T cell responses and restoring the antitumor immune system. However, effective type II ICD inducers without biotoxicity are still very limited. Herein, a tentative drug- or photosensitizer-free strategy was developed by employing enzymatic self-assembly of the peptide F-pY-T to induce mitochondrial oxidative stress in cancer cells. Upon dephosphorylation catalyzed by alkaline phosphatase overexpressed on cancer cells, the peptide F-pY-T self-assembled to form nanoparticles, which were subsequently internalized. These affected the morphology of mitochondria and induced serious reactive oxygen species production, causing the ICD characterized by the release of danger-associated molecular patterns (DAMPs). DAMPs enhanced specific immune responses by promoting the maturation of DCs and the intratumoral infiltration of tumor-specific T cells to eradicate tumor cells. The dramatic immunotherapeutic capacity could be enhanced further by combination therapy of F-pY-T and anti-PD-L1 agents without visible biotoxicity in the main organs. Thus, our results revealed an alternative strategy to induce efficient ICD by physically promoting mitochondrial oxidative stress.

     

    • HTML全文
    • 参考文献(48)
  • [1] Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-1356
    [2] Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2016; 13:143-158
    [3] Zhang X, Wang C, Wang J, Hu Q, Langworthy B, Ye Y, et al. PD-1 blockade cellular vesicles for cancer immunotherapy. Adv Mater 2018; 30:e1707112
    [4] Seliger B, Massa C. Immune therapy resistance and immune escape of tumors. Cancers (Basel) 2021; 13
    [5] Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15:3-12
    [6] Showalter A, Limaye A, Oyer JL, Igarashi R, Kittipatarin C, Copik AJ, et al. Cytokines in immunogenic cell death:applications for cancer immunotherapy. Cytokine 2017; 97:123-132
    [7] Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017; 17:97-111
    [8] Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72
    [9] Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol 2015; 6:187
    [10] Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy:present and emerging inducers. J Cell Mol Med 2019; 23:4854-4865
    [11] Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol 2007; 25:192-193
    [12] Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9:353-363
    [13] Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32:157-164
    [14] Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-875
    [15] Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw 2018; 18:e27
    [16] Schaefer L. Complexity of danger:the diverse nature of damage-associated molecular patterns. J Biol Chem 2014; 289:35237-35245
    [17] Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013; 24:319-333
    [18] Garg AD, Dudek-Peric AM, Romano E, Agostinis P. Immunogenic cell death. Int J Dev Biol 2015; 59:131-140
    [19] Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-1701
    [20] Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4:143ra99
    [21] Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482-491
    [22] Zhang K, Kaufman RJ. Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 2004; 279:25935-25938
    [23] Walter P, Ron D. The unfolded protein response:from stress pathway to homeostatic regulation. Science 2011; 334:1081-1086
    [24] Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31:1062-1079
    [25] Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med 2016; 8:328ra27
    [26] Galluzzi L, Kepp O, Kroemer G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J 2012; 31:1055-1057
    [27] Chen C, Ni X, Jia S, Liang Y, Wu X, Kong D, et al. Massively evoking immunogenic cell death by focused mitochondrial oxidative stress using an AIE luminogen with a twisted molecular structure. Adv Mater 2019; 31:e1904914
    [28] Feng B, Hou B, Xu Z, Saeed M, Yu H, Li Y. Self-amplified drug delivery with light-inducible nanocargoes to enhance cancer immunotherapy. Adv Mater 2019; 31:e1902960
    [29] Xu J, Xu L, Wang C, Yang R, Zhuang Q, Han X, et al. Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer. ACS Nano 2017; 11:4463-4474
    [30] Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release:a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 2000; 192:1001-1014
    [31] Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release:an update and review. Biochim Biophys Acta 2006; 1757:509-517
    [32] Feng Z, Han X, Wang H, Tang T, Xu B. Enzyme-instructed peptide assemblies selectively inhibit bone tumors. Chem 2019; 5:2442-2449
    [33] Wang H, Feng Z, Wang Y, Zhou R, Yang Z, Xu B. Integrating enzymatic self-assembly and mitochondria targeting for selectively killing cancer cells without acquired drug resistance. J Am Chem Soc 2016; 138:16046-16055
    [34] Du X, Zhou J, Wang H, Shi J, Kuang Y, Zeng W, et al. In situ generated D-peptidic nanofibrils as multifaceted apoptotic inducers to target cancer cells. Cell Death Dis 2017; 8:e2614
    [35] Zheng D, Chen Y, Ai S, Zhang R, Gao Z, Liang C, et al. Tandem molecular self-assembly selectively inhibits lung cancer cells by inducing endoplasmic reticulum stress. Research (Wash DC) 2019; 2019:4803624
    [36] Li X, Cai X, Zhang Z, Ding Y, Ma R, Huang F, et al. Mimetic heat shock protein mediated immune process to enhance cancer immunotherapy. Nano Lett 2020; 20:4454-4463
    [37] Ren CH, Wang ZY, Zhang XL, Gao J, Gao Y, Zhang YM, et al. Construction of all-in-one peptide nanomedicine with photoacoustic imaging guided mild hyperthermia for enhanced cancer chemotherapy. Chem Eng J 2021; 405:127008
    [38] Wang JY, Li JQ, Xiao YM, Fu B, Qin ZH. Triphenylphosphonium (TPP)-based antioxidants:a new perspective on antioxidant design. ChemMedChem 2020; 15:404-410
    [39] Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, et al. Mitochondria-targeted triphenylphosphonium-based compounds:syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev 2017; 117:10043-10120
    [40] Han X, Su R, Huang X, Wang Y, Kuang X, Zhou S, et al. Triphenylphosphonium-modified mitochondria-targeted paclitaxel nanocrystals for overcoming multidrug resistance. Asian J Pharm Sci 2019; 14:569-580
    [41] Jeena MT, Palanikumar L, Go EM, Kim I, Kang MG, Lee S, et al. Mitochondria localization induced self-assembly of peptide amphiphiles for cellular dysfunction. Nat Commun 2017; 8:26
    [42] Li X, Wang Y, Wang S, Liang C, Pu G, Chen Y, et al. A strong CD8+ T cell-stimulating supramolecular hydrogel. Nanoscale 2020; 12:2111-2117
    [43] Fishman WH. Clinical and biological significance of an isozyme tumor marker-PLAP. Clin Biochem 1987; 20:387-392
    [44] Zhan J, Cai Y, He S, Wang L, Yang Z. Tandem molecular self-assembly in liver cancer cells. Angew Chem Int Ed Engl 2018; 57:1813-1816
    [45] Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S, et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 2010; 1:e104
    [46] Vasaturo A, Verdoes M, de Vries J, Torensma R, Figdor CG. Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment. Immunobiology 2015; 220:243-248
    [47] Tuettenberg A, Schmitt E, Knop J, Jonuleit H. Dendritic cell-based immunotherapy of malignant melanoma:success and limitations. J Dtsch Dermatol Ges 2007; 5:190-196
    [48] Trahtemberg U, Mevorach D. Apoptotic cells induced signaling for immune homeostasis in macrophages and dendritic cells. Front Immunol 2017; 8:1356
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  122
  • HTML全文浏览量:  74
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-05-07
  • 修回日期:  2021-06-02
  • 录用日期:  2021-06-29
  • 网络出版日期:  2023-03-17

目录

    /

    返回文章
    返回

    Copyright © 2008 北京仁和汇智信息技术有限公司

    地址：邮政编码：100101

    电话：010-84988317，84988356，84988357传真：021-64253812Email：syzt@vip.163.com

    京公网安备 11010502036328号　京ICP备17033152号

    本系统由 北京仁和汇智信息技术有限公司 开发